United Therapeutics (UTHR) Short-Term Debt issuances (2014 - 2025)

United Therapeutics has reported Short-Term Debt issuances for 7 years, with the latest figure at $400.0 million in Q2 2025.

• Quarterly Short-Term Debt issuances rose 500.0% year-over-year to $400.0 million in Q2 2025, while the trailing twelve-month figure through Mar 2026 was $400.0 million (changed N/A YoY) and the FY2025 annual result came in at $500.0 million, changed N/A from the prior year.
• Short-Term Debt issuances climbed to $400.0 million in Q2 2025 per UTHR's latest filing, from $100.0 million in the prior quarter.
• Over five years, Short-Term Debt issuances peaked at $800.0 million in Q1 2022 and troughed at -$100.0 million in Q2 2024.
• A 4-year average of $233.3 million and a median of $100.0 million in 2023 frame the typical range for Short-Term Debt issuances.
• The widest YoY moves for Short-Term Debt issuances: up 500.0% in 2025, down 0.0% in 2025.
• Over 4 years, Short-Term Debt issuances stood at $800.0 million in 2022, then tumbled by 87.5% to $100.0 million in 2023, then slumped by 200.0% to -$100.0 million in 2024, then soared by 500.0% to $400.0 million in 2025.
• According to Business Quant data, Short-Term Debt issuances over the past three periods registered $400.0 million, $100.0 million, and -$100.0 million for Q2 2025, Q1 2025, and Q2 2024 respectively.